Loading…
Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors
A combined strategy based on the development of pharmacophore hypotheses and NMR approaches is reported for the identification of novel inhibitors of heparanase, a key enzyme involved in tumor metastasis through the remodeling of the subepithelial and subendothelial basement membranes, resulting in...
Saved in:
Published in: | Journal of computer-aided molecular design 2009-08, Vol.23 (8), p.555-569 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c369t-12f710868042cd09f2f01de3500ae0757b44e32070d6484b29834643cedc4173 |
---|---|
cites | cdi_FETCH-LOGICAL-c369t-12f710868042cd09f2f01de3500ae0757b44e32070d6484b29834643cedc4173 |
container_end_page | 569 |
container_issue | 8 |
container_start_page | 555 |
container_title | Journal of computer-aided molecular design |
container_volume | 23 |
creator | Gozalbes, Rafael Mosulén, Silvia Carbajo, Rodrigo J. Pineda-Lucena, Antonio |
description | A combined strategy based on the development of pharmacophore hypotheses and NMR approaches is reported for the identification of novel inhibitors of heparanase, a key enzyme involved in tumor metastasis through the remodeling of the subepithelial and subendothelial basement membranes, resulting in the dissemination of metastatic cancer cells. Several pharmacophore hypotheses were initially developed from the most active heparanase inhibitors known to date and, after their application to a pool of 27 known heparanase inhibitors and a database of 1,120 compounds approved by the FDA, a four-point pharmacophore model was selected as the most predictive. This model was subsequently applied to a database of 686 chemical fragments, and a subset of 100 fragments accomplishing completely or partially the four-point model was selected to perform nuclear magnetic resonance experiments to validate the hypothesis. The experimental studies confirmed the reliability of our pharmacophore model, its applicability to in silico databases in order to reduce the number of compounds to be experimentally screened, and the possibility of generating fragment libraries enriched in heparanase inhibitors. |
doi_str_mv | 10.1007/s10822-009-9269-0 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_36343327</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>36343327</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-12f710868042cd09f2f01de3500ae0757b44e32070d6484b29834643cedc4173</originalsourceid><addsrcrecordid>eNp1kctu1DAUhi0EokPhAdggiwW7wPElzniJyqWVCkioC3aWk5xMXCV2OM5U6kPwzniYEZWQWNmWv__35WPspYC3AqB5lwVspawAbGWlsRU8YhtRN6rSthaP2QashMrU-scZe5bzLZSMNfCUnQmrpWgkbNivD3iHU1pmjCv3sedfv3znd34KvV9DijwNfA4xzH7iy-hp9l1axkTIx_slrSNmzHxIxMuU7zAi_Y0N5Hd_WqfQkqdQQIwUuhF7HiIfcfHko89YVmNow5ooP2dPBj9lfHEaz9nNp483F5fV9bfPVxfvr6tOGbtWQg5NebrZgpZdD3aQA4geVQ3gEZq6abVGJaGB3uitbqXdKm206rDvtGjUOXtzrF0o_dxjXt0ccofT5COmfXbKKK2UPICv_wFv055iuZqTwqjaGDAFEkeoo5Qz4eAWKh9G906AO3hyR0-ueHIHTw5K5tWpeN_O2D8kTmIKII9ALltxh_Rw8v9bfwN1ZZ8q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216356606</pqid></control><display><type>article</type><title>Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors</title><source>Springer Link</source><creator>Gozalbes, Rafael ; Mosulén, Silvia ; Carbajo, Rodrigo J. ; Pineda-Lucena, Antonio</creator><creatorcontrib>Gozalbes, Rafael ; Mosulén, Silvia ; Carbajo, Rodrigo J. ; Pineda-Lucena, Antonio</creatorcontrib><description>A combined strategy based on the development of pharmacophore hypotheses and NMR approaches is reported for the identification of novel inhibitors of heparanase, a key enzyme involved in tumor metastasis through the remodeling of the subepithelial and subendothelial basement membranes, resulting in the dissemination of metastatic cancer cells. Several pharmacophore hypotheses were initially developed from the most active heparanase inhibitors known to date and, after their application to a pool of 27 known heparanase inhibitors and a database of 1,120 compounds approved by the FDA, a four-point pharmacophore model was selected as the most predictive. This model was subsequently applied to a database of 686 chemical fragments, and a subset of 100 fragments accomplishing completely or partially the four-point model was selected to perform nuclear magnetic resonance experiments to validate the hypothesis. The experimental studies confirmed the reliability of our pharmacophore model, its applicability to in silico databases in order to reduce the number of compounds to be experimentally screened, and the possibility of generating fragment libraries enriched in heparanase inhibitors.</description><identifier>ISSN: 0920-654X</identifier><identifier>EISSN: 1573-4951</identifier><identifier>DOI: 10.1007/s10822-009-9269-0</identifier><identifier>PMID: 19421720</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Animal Anatomy ; Binding Sites ; Biotechnology ; Cancer ; Chemistry ; Chemistry and Materials Science ; Computer Applications in Chemistry ; Computer-Aided Design ; Drug Discovery ; Enzymes ; Glucuronidase - antagonists & inhibitors ; Glucuronidase - chemistry ; Histology ; Humans ; Inhibitors ; Ligands ; Magnetic Resonance Spectroscopy ; Morphology ; NMR ; Nuclear magnetic resonance ; Pharmacology ; Physical Chemistry ; Protein Binding ; Protein Conformation ; Small Molecule Libraries - chemistry ; Small Molecule Libraries - therapeutic use ; Structure-Activity Relationship</subject><ispartof>Journal of computer-aided molecular design, 2009-08, Vol.23 (8), p.555-569</ispartof><rights>Springer Science+Business Media B.V. 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-12f710868042cd09f2f01de3500ae0757b44e32070d6484b29834643cedc4173</citedby><cites>FETCH-LOGICAL-c369t-12f710868042cd09f2f01de3500ae0757b44e32070d6484b29834643cedc4173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19421720$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gozalbes, Rafael</creatorcontrib><creatorcontrib>Mosulén, Silvia</creatorcontrib><creatorcontrib>Carbajo, Rodrigo J.</creatorcontrib><creatorcontrib>Pineda-Lucena, Antonio</creatorcontrib><title>Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors</title><title>Journal of computer-aided molecular design</title><addtitle>J Comput Aided Mol Des</addtitle><addtitle>J Comput Aided Mol Des</addtitle><description>A combined strategy based on the development of pharmacophore hypotheses and NMR approaches is reported for the identification of novel inhibitors of heparanase, a key enzyme involved in tumor metastasis through the remodeling of the subepithelial and subendothelial basement membranes, resulting in the dissemination of metastatic cancer cells. Several pharmacophore hypotheses were initially developed from the most active heparanase inhibitors known to date and, after their application to a pool of 27 known heparanase inhibitors and a database of 1,120 compounds approved by the FDA, a four-point pharmacophore model was selected as the most predictive. This model was subsequently applied to a database of 686 chemical fragments, and a subset of 100 fragments accomplishing completely or partially the four-point model was selected to perform nuclear magnetic resonance experiments to validate the hypothesis. The experimental studies confirmed the reliability of our pharmacophore model, its applicability to in silico databases in order to reduce the number of compounds to be experimentally screened, and the possibility of generating fragment libraries enriched in heparanase inhibitors.</description><subject>Animal Anatomy</subject><subject>Binding Sites</subject><subject>Biotechnology</subject><subject>Cancer</subject><subject>Chemistry</subject><subject>Chemistry and Materials Science</subject><subject>Computer Applications in Chemistry</subject><subject>Computer-Aided Design</subject><subject>Drug Discovery</subject><subject>Enzymes</subject><subject>Glucuronidase - antagonists & inhibitors</subject><subject>Glucuronidase - chemistry</subject><subject>Histology</subject><subject>Humans</subject><subject>Inhibitors</subject><subject>Ligands</subject><subject>Magnetic Resonance Spectroscopy</subject><subject>Morphology</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Pharmacology</subject><subject>Physical Chemistry</subject><subject>Protein Binding</subject><subject>Protein Conformation</subject><subject>Small Molecule Libraries - chemistry</subject><subject>Small Molecule Libraries - therapeutic use</subject><subject>Structure-Activity Relationship</subject><issn>0920-654X</issn><issn>1573-4951</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp1kctu1DAUhi0EokPhAdggiwW7wPElzniJyqWVCkioC3aWk5xMXCV2OM5U6kPwzniYEZWQWNmWv__35WPspYC3AqB5lwVspawAbGWlsRU8YhtRN6rSthaP2QashMrU-scZe5bzLZSMNfCUnQmrpWgkbNivD3iHU1pmjCv3sedfv3znd34KvV9DijwNfA4xzH7iy-hp9l1axkTIx_slrSNmzHxIxMuU7zAi_Y0N5Hd_WqfQkqdQQIwUuhF7HiIfcfHko89YVmNow5ooP2dPBj9lfHEaz9nNp483F5fV9bfPVxfvr6tOGbtWQg5NebrZgpZdD3aQA4geVQ3gEZq6abVGJaGB3uitbqXdKm206rDvtGjUOXtzrF0o_dxjXt0ccofT5COmfXbKKK2UPICv_wFv055iuZqTwqjaGDAFEkeoo5Qz4eAWKh9G906AO3hyR0-ueHIHTw5K5tWpeN_O2D8kTmIKII9ALltxh_Rw8v9bfwN1ZZ8q</recordid><startdate>20090801</startdate><enddate>20090801</enddate><creator>Gozalbes, Rafael</creator><creator>Mosulén, Silvia</creator><creator>Carbajo, Rodrigo J.</creator><creator>Pineda-Lucena, Antonio</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7SC</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AL</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>BKSAR</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>JQ2</scope><scope>K7-</scope><scope>K9.</scope><scope>KB.</scope><scope>L7M</scope><scope>L~C</scope><scope>L~D</scope><scope>M0N</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>P5Z</scope><scope>P62</scope><scope>PCBAR</scope><scope>PDBOC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>20090801</creationdate><title>Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors</title><author>Gozalbes, Rafael ; Mosulén, Silvia ; Carbajo, Rodrigo J. ; Pineda-Lucena, Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-12f710868042cd09f2f01de3500ae0757b44e32070d6484b29834643cedc4173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animal Anatomy</topic><topic>Binding Sites</topic><topic>Biotechnology</topic><topic>Cancer</topic><topic>Chemistry</topic><topic>Chemistry and Materials Science</topic><topic>Computer Applications in Chemistry</topic><topic>Computer-Aided Design</topic><topic>Drug Discovery</topic><topic>Enzymes</topic><topic>Glucuronidase - antagonists & inhibitors</topic><topic>Glucuronidase - chemistry</topic><topic>Histology</topic><topic>Humans</topic><topic>Inhibitors</topic><topic>Ligands</topic><topic>Magnetic Resonance Spectroscopy</topic><topic>Morphology</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Pharmacology</topic><topic>Physical Chemistry</topic><topic>Protein Binding</topic><topic>Protein Conformation</topic><topic>Small Molecule Libraries - chemistry</topic><topic>Small Molecule Libraries - therapeutic use</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gozalbes, Rafael</creatorcontrib><creatorcontrib>Mosulén, Silvia</creatorcontrib><creatorcontrib>Carbajo, Rodrigo J.</creatorcontrib><creatorcontrib>Pineda-Lucena, Antonio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Computer and Information Systems Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Computing Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Earth, Atmospheric & Aquatic Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Computer Science Collection</collection><collection>Computer Science Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>https://resources.nclive.org/materials</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Computer and Information Systems Abstracts Academic</collection><collection>Computer and Information Systems Abstracts Professional</collection><collection>Computing Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database (ProQuest)</collection><collection>ProQuest Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Earth, Atmospheric & Aquatic Science Database</collection><collection>Materials Science Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Journal of computer-aided molecular design</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gozalbes, Rafael</au><au>Mosulén, Silvia</au><au>Carbajo, Rodrigo J.</au><au>Pineda-Lucena, Antonio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors</atitle><jtitle>Journal of computer-aided molecular design</jtitle><stitle>J Comput Aided Mol Des</stitle><addtitle>J Comput Aided Mol Des</addtitle><date>2009-08-01</date><risdate>2009</risdate><volume>23</volume><issue>8</issue><spage>555</spage><epage>569</epage><pages>555-569</pages><issn>0920-654X</issn><eissn>1573-4951</eissn><abstract>A combined strategy based on the development of pharmacophore hypotheses and NMR approaches is reported for the identification of novel inhibitors of heparanase, a key enzyme involved in tumor metastasis through the remodeling of the subepithelial and subendothelial basement membranes, resulting in the dissemination of metastatic cancer cells. Several pharmacophore hypotheses were initially developed from the most active heparanase inhibitors known to date and, after their application to a pool of 27 known heparanase inhibitors and a database of 1,120 compounds approved by the FDA, a four-point pharmacophore model was selected as the most predictive. This model was subsequently applied to a database of 686 chemical fragments, and a subset of 100 fragments accomplishing completely or partially the four-point model was selected to perform nuclear magnetic resonance experiments to validate the hypothesis. The experimental studies confirmed the reliability of our pharmacophore model, its applicability to in silico databases in order to reduce the number of compounds to be experimentally screened, and the possibility of generating fragment libraries enriched in heparanase inhibitors.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>19421720</pmid><doi>10.1007/s10822-009-9269-0</doi><tpages>15</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0920-654X |
ispartof | Journal of computer-aided molecular design, 2009-08, Vol.23 (8), p.555-569 |
issn | 0920-654X 1573-4951 |
language | eng |
recordid | cdi_proquest_miscellaneous_36343327 |
source | Springer Link |
subjects | Animal Anatomy Binding Sites Biotechnology Cancer Chemistry Chemistry and Materials Science Computer Applications in Chemistry Computer-Aided Design Drug Discovery Enzymes Glucuronidase - antagonists & inhibitors Glucuronidase - chemistry Histology Humans Inhibitors Ligands Magnetic Resonance Spectroscopy Morphology NMR Nuclear magnetic resonance Pharmacology Physical Chemistry Protein Binding Protein Conformation Small Molecule Libraries - chemistry Small Molecule Libraries - therapeutic use Structure-Activity Relationship |
title | Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A31%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20and%20NMR%20validation%20of%20minimal%20pharmacophore%20hypotheses%20for%20the%20generation%20of%20fragment%20libraries%20enriched%20in%20heparanase%20inhibitors&rft.jtitle=Journal%20of%20computer-aided%20molecular%20design&rft.au=Gozalbes,%20Rafael&rft.date=2009-08-01&rft.volume=23&rft.issue=8&rft.spage=555&rft.epage=569&rft.pages=555-569&rft.issn=0920-654X&rft.eissn=1573-4951&rft_id=info:doi/10.1007/s10822-009-9269-0&rft_dat=%3Cproquest_cross%3E36343327%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c369t-12f710868042cd09f2f01de3500ae0757b44e32070d6484b29834643cedc4173%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=216356606&rft_id=info:pmid/19421720&rfr_iscdi=true |